The End of the Pharmaceutical Blockbuster
Executive Summary
The 90's have seen a pharmaceutical industry dominated by "mega blockbusters." But according to a study published by the Boston Consulting Group, the days of the blockbuster as a vehicle for sustainable success are limited. Rather, drug companies will gradually move away from broad-scale products with lower efficacy toward targeted products that offer greater efficacy to smaller patient populations. The shift away from blockbusters will be driven by pharmacogenomics but also by "consumer-centric care."
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.